Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed outlook. While there are positive elements like the HRScale rollout and strategic partnerships, concerns about elevated benefits costs, uncertain client transitions, and a lack of specific guidance on profitability metrics temper enthusiasm. The Q&A section highlights management's reluctance to provide specific details, adding to uncertainty. Given the company's mid-cap size, these factors suggest a neutral stock price reaction in the short term.
Adjusted EPS for Q4 2025 Minus $0.60, a decrease compared to the previous year. The decline was due to accelerated sales office consolidation expenses of $2.8 million. Excluding this expense, adjusted EPS was negative $0.54.
Adjusted EBITDA for Q4 2025 Minus $13 million, a decrease compared to the previous year. Excluding the $2.8 million sales office consolidation expense, adjusted EBITDA was minus $11 million.
Average number of paid worksite employees in Q4 2025 312,377, an increase of 1.1% over Q4 2024. This was slightly below the forecasted range due to continued weakness and volatility in client net hiring.
Worksite employees paid from new clients in Q4 2025 Increased by 6% over Q4 2024. This growth was attributed to new client acquisition.
Client retention in Q4 2025 Averaged 99% per month, consistent with prior year results.
Gross profit per worksite employee in Q4 2025 $183 per month, generally in line with the forecast. Benefits costs were within the expected range, with higher-than-expected healthcare claims offset by favorable results in other benefits components.
Operating expenses in Q4 2025 Decreased by 6% compared to Q4 2024. This included $2.8 million related to accelerated sales office consolidation.
Investment in HRScale in Q4 2025 $15 million, including $10 million in operating expenses and $5 million in capitalized costs. This was a decrease from $19 million in Q4 2024, all of which was expensed.
Dividends paid in Q4 2025 $22 million. For the full year, $90 million in cash dividends were paid.
Stock repurchase in 2025 232,000 shares repurchased at a cost of $19 million.
Adjusted cash at the end of Q4 2025 $57 million.
Credit facility amendment in Q4 2025 Extended maturity date to December 15, 2028, increased borrowing capacity from $650 million to $750 million, and raised the maximum leverage ratio from 3x to 3.75x EBITDA.
Average number of worksite employees paid in 2025 Just over 310,000, an increase of 1% compared to 2024.
Adjusted EBITDA for 2025 $131 million, a decline of 51% compared to 2024. The decline was attributed to increased benefits costs and macroeconomic factors.
Adjusted EPS for 2025 $1.03, a decline of 71% compared to 2024. The decline was attributed to increased benefits costs and macroeconomic factors.
HRScale investment in 2025 $59 million, including $48 million expensed and $11 million capitalized.
HRScale rollout: Invested $15 million in Q4 2025, including $10 million in operating expenses and $5 million in capitalized costs. Beta clients scheduled to go live in March 2026, with payroll starting April 1. Expected to have 6,000-8,000 paid worksite employees on HRScale by year-end 2026.
HR360 enhancements: Focused on margin recovery and growth momentum. New tools and processes introduced to support client selection and pricing. Sales efficiency improved by 13% in 2025.
Market expansion with HRScale: HRScale targets mid-market companies (150-5,000 employees), increasing total addressable market and advancing growth model. Early activity levels indicate strong demand.
Sales office consolidation: Accelerated in Q4 2025, incurring $2.8 million in additional operating expenses.
Organizational rightsizing: Reduced non-sales staff by 4%, expected to save $20 million in 2026, excluding a $9 million restructuring charge.
Credit facility amendment: Extended maturity to December 2028, increased borrowing capacity to $750 million, and raised maximum leverage ratio to 3.75x EBITDA.
Three-year plan: Focused on margin recovery in 2026, balanced growth and profitability in 2027, and high-performance metrics in 2028. Aims to return to double-digit revenue and gross profit growth.
Client pricing and selection strategy: Implemented to improve gross profit margins. Approximately 60% of clients yet to receive updated pricing in 2026.
Macroeconomic Uncertainty: Ongoing uncertainty in the small- and medium-sized business market and employment stagnation negatively impacted growth and profitability in 2025. This trend is expected to continue into 2026.
Health Care Costs: Industry-wide increase in health care claim costs caused a significant gross profit margin squeeze in 2025 and is expected to remain elevated in 2026.
Client Net Hiring Volatility: Client net hiring was weaker than expected, with unexpected net reductions in November 2025, impacting the number of paid worksite employees.
Sales Office Consolidation: Accelerated sales office consolidation resulted in additional operating expenses of $2.8 million in Q4 2025.
Attrition and Non-Renewals: Higher-than-expected attrition and company-initiated non-renewals due to margin recovery pricing contributed to fewer paid worksite employees and lower projected growth for 2026.
Rightsizing of Organization: A decision to reduce non-sales staff by 4% to align with future needs, which includes a $9 million restructuring charge.
HRScale Deployment Costs: Significant investment in HRScale, including $59 million in 2025, with ongoing costs expected in 2026, though at a reduced level.
Credit Facility Amendments: Amendments to the credit facility increased borrowing capacity and leverage ratio, but also reflect reliance on external financing.
Client Selection and Pricing Adjustments: New tools and processes for client selection and pricing, while aiding margin recovery, contributed to lower-than-expected new booked sales in late 2025.
Revenue Growth: For 2026, the company expects growth in average paid worksite employees to range from -1.5% to +1.5% compared to 2025. This reflects a lower starting point due to challenges in 2025, including client attrition and lower-than-expected new booked sales.
Profitability Recovery: The company anticipates significant improvement in gross profit per worksite employee throughout 2026, driven by pricing and client selection strategies, renegotiated contracts with UnitedHealthcare, and plan design changes. Adjusted EBITDA is forecasted to increase by 30% to 76%, reaching a range of $170 million to $230 million.
HRScale Rollout: The HRScale solution is expected to drive growth in the mid-market segment, with 6,000 to 8,000 paid worksite employees projected to be on HRScale by year-end 2026. The rollout includes beta clients going live in Q2, with a focus on onboarding and servicing clients efficiently.
Operating Expenses: Operating expenses are expected to decrease in 2026 due to a 4% reduction in non-sales headcount and lower HRScale investment costs. The company plans to reinvest some savings into marketing, sales capacity, and HRScale service capacity.
Market Trends and Challenges: The company expects elevated health care cost trends to persist in 2026 but plans to mitigate these through pricing adjustments, client selection strategies, and alternative benefit offerings. The labor market uncertainty in the small- and medium-sized business sector is also expected to continue.
Three-Year Plan: The company has initiated a three-year plan targeting margin recovery in 2026, balanced growth and profitability in 2027, and high-performance key metrics in 2028. This includes double-digit revenue and gross profit growth and adjusted EBITDA growth rates exceeding 20% annually.
Q4 2025 Dividends Paid: $22 million
2025 Total Dividends Paid: $90 million
2025 Share Repurchase: 232,000 shares at a cost of $19 million
The earnings call summary presents a mixed outlook. While there are positive elements like the HRScale rollout and strategic partnerships, concerns about elevated benefits costs, uncertain client transitions, and a lack of specific guidance on profitability metrics temper enthusiasm. The Q&A section highlights management's reluctance to provide specific details, adding to uncertainty. Given the company's mid-cap size, these factors suggest a neutral stock price reaction in the short term.
The earnings call revealed disappointing financial results with an EPS miss and lower EBITDA due to high benefits costs. Despite a positive outlook for 2026, the immediate financials are concerning. The Q&A highlighted management's optimism about future recovery and strong sales, but did not address current issues effectively. With a market cap of ~$3.4 billion, the negative financial results and uncertainty in guidance are likely to lead to a negative stock price movement in the short term.
The earnings call presents a mixed picture: strong client retention and efficient sales are positive, but reduced growth guidance and declining gross profit per employee are concerns. The Q&A reveals optimism about future growth and strategic initiatives, yet lacks concrete guidance on the Workday partnership's financial impact. The partnership with Workday and share repurchases provide some optimism, but increased healthcare costs and uncertain future projections temper enthusiasm. Given the market cap of $3.44 billion, the stock price is likely to remain stable, resulting in a neutral prediction.
The earnings call reveals several negative factors: disappointing financial results with missed EPS and EBITDA guidance, higher-than-expected benefits costs, and delays in client onboarding. The Q&A section highlights uncertainties due to government actions and healthcare cost volatility, with management providing unclear responses. Despite some positive elements like share repurchases and a strategic partnership with Workday, the immediate outlook is clouded by these challenges. Given the market cap and the negative sentiment from analysts, the stock price is likely to see a negative reaction in the range of -2% to -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.